Showing results (91-100 of 178) with videos related to

Sort By:
Pageof 18
Biorxiv : the Preprint Server for Biology|July 3, 2026
A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World DatasetsAveri Perny, Vipul Jarmale, Jay Jasti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2022
ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell CarcinomaAditi Mulgaonkar, Roy Elias, Layton Woolford, et al.
Advances in Radiation Oncology|August 12, 2025
Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell CarcinomaMihailo Miljanic, Tidie Song, Alana Christie, et al.
Journal for Immunotherapy of Cancer|June 4, 2019
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab responseJoseph Vento, Aditi Mulgaonkar, Layton Woolford, et al.
European Urology Oncology|January 6, 2022
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney CancerRaquibul Hannan, Michael Christensen, Hans Hammers, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 20, 2021
Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidneyPayal Kapur, Ming Gao, Hua Zhong, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2024
Unconventional mechanism of action and resistance to rapalogs in renal cancerJuan Yang, Ramesh Butti, Shannon Cohn, et al.
Arxiv|June 10, 2024
Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical TrialJay Jasti, Hua Zhong, Vandana Panwar, et al.
Nature Communications|March 18, 2025
Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trialJay Jasti, Hua Zhong, Vandana Panwar, et al.
BMC Urology|March 23, 2017
BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumorJeanette E Eckel-Passow, Daniel J Serie, John C Cheville, et al.
Pageof 18